Navigation Links
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/18/2007

Data Presented at the World Muscle Society International Congress

SOUTH PLAINFIELD, N.J., Oct. 18 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced additional data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation. The results, which include data from all three cohorts of the study, show that administration of PTC124 is associated with qualitative increases in muscle dystrophin expression and with reductions in serum creatine kinase values. These data were presented today at the World Muscle Society (WMS) International Congress in Taormina, Italy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

Patients with DMD are boys and young men who lack dystrophin, a protein that is critical to the structural stability of muscle fibers. This Phase 2 multi-site, open-label, dose-ranging clinical trial enrolled 38 boys with loss of dystrophin due to a nonsense mutation in the dystrophin gene. Participants also had substantially elevated serum creatine kinase levels due to the disease, and symptoms associated with DMD. Boys enrolled in the trial received 28 days of PTC124 treatment at one of three dose levels, with the primary endpoint of the trial being an increase in dystrophin expression in muscle. Pre- and post-treatment muscle biopsies and blood analyses to assess muscle-derived creatine kinase were available from all 38 patients.

An in vitro analysis demonstrated PTC124-induced dystrophin expression in cultured muscle cells from all 35 (100%) of the boys with samples evaluable in this analysis. The in vivo data indicated that, across all three dose levels of PTC124, 18/38 (47%) of patients demonstrated visib
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
... shows, investigational regimen resulted in 82 percent overall survival and 78 ... ... is presently being conducted in this ... patient population, LUGANO, Switzerland, June 9 In an ...
Cached Medicine Technology:Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 2Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 3Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 4
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
(Date:7/25/2014)... As reported by Wood TV 8 in the article ... seen a nearly 500-person increase in heroin related overdose deaths ... between 1999 and 2002, the toll increased to 728 during ... states, drug users in Michigan have turned to heroin after ... the price of both substances, noting that an 80-milligram pill ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Reproductive Science ... announce that Dr. Kerri Luzzo, Lead Physician at RSC ... for her professional accomplishments in fertility care and community ... At the 10th Annual PBN Awards ceremony held July ... 40 of the most highly regarded, emerging leaders in ...
(Date:7/25/2014)... 25, 2014 As reported by People Magazine ... After Jersey Shore and Getting Sober (7/15), one of ... Shore, has spoken out to the public about his personal ... show, The Situation admits that moving on with his life ... drugs, and other drugs in 2012 and even spent some ...
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational partnership ... come and make a difference in the Tampa Bay community. ... to provide the support needed to keep the science center ... the IMAX Dome Theatre from film to a state-of-the-art digital ... Theatre in the state of Florida, and it is one ...
Breaking Medicine News(10 mins):Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4
... and ... Children,s Hospital Boston, BOSTON, April 8, 2008 Hess ... help support,children with medical needs through the Jimmy Fund and the ... every home run hit during a New,England Sports Network (NESN) televised ...
... Building Innovations, Products Help Protect and Preserve Buildings, ... DuPont (NYSE:,DD) and The Energy and Resources Institute ... the cause of green building design and,certification in ... Kalsi, president of DuPont India,and Dr. R. K. ...
... Distort State Funding, HARRISBURG, Pa., April 8, ... by more than $500 million in the past ... today expressed,continuing concern about misleading claims from nursing ... Pennsylvania,s nursing,home facilities., "Nursing home representatives seem ...
... PITTSBURGH, April 8, 2008 Precision Therapeutics ... it signed contracts with,National Preferred Provider Network ... NPPN, headquartered in Middletown, NY, is ... country representing more than seven million lives. ...
... at Events Nationwide Saturday, April 12, to Help ... 8, 2008 On Saturday, April 12, more than,600,000 ... Healthy,Kids(R) Day -- the nation,s largest health day for ... YMCA Healthy Kids Day encourages families,to "Put Play in ...
... Auctions off Flight Simulator Experience on eBay, ... one lucky guest in the captain,s seat in ... Cancer Society (ACS), United is auctioning off a,behind-the-scenes ... Flight Training Center in Denver, Colo., including two ...
Cached Medicine News:Health News:Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs 2Health News:Every Boston Red Sox Home Run Televised on NESN in 2008 to Help Children With Medical Needs 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 2Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 4Health News:Precision Therapeutics Adds 8 Million Covered Lives Under Contract 2Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 2Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 3Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 4Health News:YMCA of the USA Celebrates 'YMCA Healthy Kids(R) Day,' the Nation's Largest Health Day for Children and Families 5Health News:Be in the Captain's Seat in the Fight Against Cancer 2Health News:Be in the Captain's Seat in the Fight Against Cancer 3
The precise, fully reusable R-100 Pullback Device is an invaluable tool during plaque volumetric analysis....
... you perform exams from cardiac to angio. ... no compromises. An ideal 31 centimeters square, ... of cardiovascular and interventional imaging. With a ... variety of vascular and interventional procedures. The ...
... The RX daytona is a fully ... field in bench top analysers offering many ... standing systems. With reusable glass cuvettes, on ... and reagents, the random access analyser can ...
Inquire...
Medicine Products: